EP1352072A4 - Nucleic acid delivery formulations - Google Patents

Nucleic acid delivery formulations

Info

Publication number
EP1352072A4
EP1352072A4 EP02713428A EP02713428A EP1352072A4 EP 1352072 A4 EP1352072 A4 EP 1352072A4 EP 02713428 A EP02713428 A EP 02713428A EP 02713428 A EP02713428 A EP 02713428A EP 1352072 A4 EP1352072 A4 EP 1352072A4
Authority
EP
European Patent Office
Prior art keywords
nucleic acid
acid delivery
delivery formulations
formulations
nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02713428A
Other languages
German (de)
French (fr)
Other versions
EP1352072A2 (en
Inventor
Shikha P Barman
Krishnendu Roy
Mary Lynne Hedley
Daqing Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MGI Pharma Biologics Inc
Original Assignee
Zycos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zycos Inc filed Critical Zycos Inc
Publication of EP1352072A2 publication Critical patent/EP1352072A2/en
Publication of EP1352072A4 publication Critical patent/EP1352072A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
EP02713428A 2001-01-17 2002-01-17 Nucleic acid delivery formulations Withdrawn EP1352072A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US26221901P 2001-01-17 2001-01-17
US262219P 2001-01-17
US27025601P 2001-02-20 2001-02-20
US270256P 2001-02-20
US30048401P 2001-06-22 2001-06-22
US300484P 2001-06-22
PCT/US2002/001379 WO2002057424A2 (en) 2001-01-17 2002-01-17 Nucleic acid delivery formulations

Publications (2)

Publication Number Publication Date
EP1352072A2 EP1352072A2 (en) 2003-10-15
EP1352072A4 true EP1352072A4 (en) 2004-09-01

Family

ID=27401491

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02713428A Withdrawn EP1352072A4 (en) 2001-01-17 2002-01-17 Nucleic acid delivery formulations

Country Status (4)

Country Link
EP (1) EP1352072A4 (en)
JP (1) JP2004521109A (en)
CA (1) CA2435287A1 (en)
WO (1) WO2002057424A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375096B1 (en) 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
JP2005530695A (en) * 2002-02-15 2005-10-13 ザイコス インク． Electroporation method for introducing physiologically active substances into cells
KR20140070676A (en) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
CN101415443A (en) * 2003-10-23 2009-04-22 阿尔扎公司 Compositions of stabilized DNA for coating microprojctions
WO2006053836A1 (en) * 2004-11-16 2006-05-26 Universite De Liege Active substance delivery system comprising a hydrogel atrix and microcarriers
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
EP2700414B1 (en) * 2011-04-19 2019-11-13 Kyoto University Self-gelatinizable nucleic acid
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2016116922A1 (en) * 2015-01-19 2016-07-28 Rappaport Family Institute For Research In The Medical Sciences Ubiquitin ligase kpc1 promotes processing of p105 nf-kappab1 to p50, eliciting strong tumor suppression
KR101637883B1 (en) * 2015-09-30 2016-07-21 선바이오(주) Polyethylene glycol hydrogel injection
KR101666792B1 (en) * 2016-02-05 2016-10-17 주식회사 파마리서치프로덕트 Thermosensitive hydrogel composition containing nucleic acid and chitosan
CN111333878B (en) * 2019-05-23 2020-11-10 吾奇生物医疗科技(镇江)有限公司 Double-crosslinked chitosan hydrogel and preparation method and application thereof
CN109134855B (en) * 2018-07-23 2021-03-23 安徽大学 Acid-sensitive cationic polymer POEAMAM of polyamide amine and preparation method and application thereof
CN113683780B (en) * 2021-09-15 2022-07-05 广州医科大学 Antiserum and low-cytotoxicity polyamino acid gene delivery carrier material with membrane penetrating activity and nucleus positioning function

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0987029A1 (en) * 1998-08-28 2000-03-22 Transgene S.A. Use of a catonic polymer for the preparation of a complex with nucleic acid and related compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3940316A1 (en) * 1989-12-06 1991-06-13 Bollig & Kemper AQUEOUS DISPERSIONS OF CROSS-LINKED POLYMER MICROPARTICLES
US5534259A (en) * 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US6132765A (en) * 1996-04-12 2000-10-17 Uroteq Inc. Drug delivery via therapeutic hydrogels
WO1998001162A2 (en) * 1996-07-09 1998-01-15 The Johns Hopkins University Gene delivery system
AU4907897A (en) * 1996-10-11 1998-05-11 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
WO1999001533A1 (en) * 1997-06-30 1999-01-14 Ciba Specialty Chemicals Water Treatments Limited Polymeric materials and their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0987029A1 (en) * 1998-08-28 2000-03-22 Transgene S.A. Use of a catonic polymer for the preparation of a complex with nucleic acid and related compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KABANOV A V ET AL: "DNA COMPLEXES WITH POLYCATIONS FOR THE DELIVERY OF GENETIC MATERIALINTO CELLS", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 6, no. 1, 1995, pages 7 - 20, XP000494803, ISSN: 1043-1802 *
MATTSON G ET AL: "A practical approach to crosslinking.", MOLECULAR BIOLOGY REPORTS. APR 1993, vol. 17, no. 3, April 1993 (1993-04-01), pages 167 - 183, XP009033258, ISSN: 0301-4851 *

Also Published As

Publication number Publication date
JP2004521109A (en) 2004-07-15
EP1352072A2 (en) 2003-10-15
WO2002057424A2 (en) 2002-07-25
WO2002057424A3 (en) 2002-10-03
CA2435287A1 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
AU2002303243A1 (en) Imaging nucleic acid delivery
GB0319041D0 (en) Pharmaceutical Formulations
EP1404860A4 (en) Delivery system for nucleic acids
IL162042A0 (en) Liposome composition for delivery of nucleic acid
HUP0302847A3 (en) Pharmaceutical formulation comprising bicalutamide
IL159532A0 (en) Enteral formulations
GB0012997D0 (en) Gene delivery
EP1391209A4 (en) Protein formulations
EP1352072A4 (en) Nucleic acid delivery formulations
GB0120701D0 (en) Pharmaceutical formulations
GB0103638D0 (en) Pharmaceutical formulations
GB0121715D0 (en) Pharmaceutical formulations
AU2002365188A8 (en) Nucleic acid delivery and expression
IL161902A0 (en) Pharmaceutical formulation comprising bicalutamide
GB2380129B (en) Pharmaceutical formulations
GB0105560D0 (en) Pharmaceutical formulations
EP1446488A4 (en) Regulated nucleic acid expression system
AU2002366435A8 (en) Nucleic acid amplification
IL158172A0 (en) Pharmaceutical compositions containing (-)-hydroxycitric acid
GB0124455D0 (en) Pharmaceutical formulations
GB0112585D0 (en) Nucleic acid delivery
GB0110525D0 (en) Nucleic acid delivery
AU2002347346A8 (en) Dna vaccine
EP1387892A4 (en) Gene delivery compounds
GB0026892D0 (en) Nucleic acid delivery

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030728

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040719

17Q First examination report despatched

Effective date: 20070126

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070807